Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.55 |
| ▸ | FLT3 | P36888 | 8/20 | 0.55 |
| ▸ | KIT | P10721 | 8/20 | 0.55 |
| ▸ | LCK | P06239 | 6/20 | 0.55 |
| ▸ | RET | P07949 | 6/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.55 |
| ▸ | ABL1 | P00519 | 5/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.55 |
| ▸ | CSF1R | P07333 | 5/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.55 |
| ▸ | FLT1 | P17948 | 5/20 | 0.55 |
| ▸ | CLK2 | P49760 | 5/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.55 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.55 |
| ▸ | TAOK1 | Q7L7X3 | 5/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.55 |
| ▸ | GSK3B | P49841 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31165911 | 1.00 | KDR (0.55) | KDRFLT3KITLCKRET | |
| SCHEMBL4470227 | 0.83 | KDR (0.55) | KDRFLT3KITLCKRET | |
| SCHEMBL31165895 | 0.83 | KDR (0.55) | KDRFLT3KITLCKRET | |
| SCHEMBL4489600 | 0.80 | KDR (0.59) | KDRFLT3KITLCKRET | |
| SCHEMBL4486113 | 0.77 | KDR (0.77) | KDRFLT3KITLCKRET | |
| SCHEMBL21436418 | 0.77 | KDR (0.62) | KDRFLT3KITLCKRET | |
| SCHEMBL31165917 | 0.77 | KDR (0.62) | KDRFLT3KITLCKRET | |
| SCHEMBL3529866 | 0.77 | KDR (0.62) | KDRFLT3KITLCKRET | |
| SCHEMBL4477226 | 0.77 | KDR (0.85) | KDRFLT3KITLCKRET | |
| SCHEMBL31165898 | 0.76 | KDR (0.61) | KDRFLT3KITLCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| EP-3774797-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | Merck Patent GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| CN-112236429-A | Heteroaryl compounds as type II IRAK inhibitors and uses thereof | 默克专利有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019192962-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019192962-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| EP-1487841-B1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885FLT3 29/4885KIT 394/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | KDR 391/4885FLT3 16/4885KIT 361/4885 |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDR 1533/4885FLT3 52/4885KIT 1517/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885FLT3 29/4885KIT 394/4885 |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | IRAK2, IRAK3, IRAK1 | KDR 1367/4885FLT3 34/4885KIT 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.